Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Bacillus anthracis is complex because of its spore form. The spore is invulnerable to antibiotic action. It also has an impact on the emergence of resistance. We employed the hollow-fiber infection model to study the impacts of different doses and schedules of moxifloxacin on the total-organism population, the spore population, and the subpopulations of vegetative- and spore-phase organisms that were resistant to moxifloxacin. We then generated a mathematical model of the impact of moxifloxacin, administered by continuous infusion or once daily, on vegetative- and spore-phase organisms. The ratio of the rate constant for vegetative-phase cells going to spore phase (K(vs)) to the rate constant for spore-phase cells going to vegetative phase (K(sv)) determines the rate of organism clearance. The continuous-infusion drug profile is more easily sensed as a threat; the K(vs)/K(sv) ratio increases at lower drug exposures (possibly related to quorum sensing). This movement to spore phase protects the organism but makes the emergence of resistance less likely. Suppression of resistance requires a higher level of drug exposure with once-daily administration than with a continuous infusion, a difference that is related to vegetative-to-spore (and back) transitioning. Spore biology has a major impact on drug therapy and resistance suppression. These findings explain why all drugs of different classes have approximately the same rate of organism clearance for Bacillus anthracis.
Drusano
G L
GL
Ordway Research Institute, 150 New Scotland Ave., Albany, NY 12208, USA. gdrusano@ordwayresearch.org
Okusanya
O O
OO
Okusanya
A O
AO
van Scoy
B
B
Brown
D L
DL
Fregeau
C
C
Kulawy
R
R
Kinzig
M
M
Sörgel
F
F
Heine
H S
HS
Louie
A
A
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D001408:Bacillus anthracis / Q000187:drug effects* / Q000502:physiology; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D000077266:Moxifloxacin; D011804:Quinolines / Q000494:pharmacology*; D013171:Spores, Bacterial / Q000502:physiology
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin
J Infect Dis. 2005 Jun 1;191(11):1881-8
15871122
Antimicrob Agents Chemother. 2005 Dec;49(12):5099-106
16304178
Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7
10543767
Antimicrob Agents Chemother. 2008 Jul;52(7):2486-96
18458134
Antimicrob Agents Chemother. 2007 Aug;51(8):2661-7
17517837
J Infect Dis. 2007 Sep 1;196(5):782-7
17674322